Vaso-Occlusive Crisis clinical trials at UCSF
2 in progress, 1 open to eligible people
A vaso-occlusive crisis is a painful event in sickle cell disease. UCSF is studying the long-term safety of a medicine called inclacumab in patients with this disease. This research focuses on how safe inclacumab is when used for a long time.
Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease
open to eligible people ages 12 years and up
This study is an open-label study to evaluate the safety of long-term administration of inclacumab in participants with sickle cell disease (SCD). Participants in this study will have completed a prior study of inclacumab.
Oakland, California and other locations
Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Sorry, in progress, not accepting new patients
This Phase 3 study will assess the safety and efficacy of inclacumab, a P-selectin inhibitor, in reducing the frequency of vaso-occlusive crises (VOCs) in approximately 240 adult and adolescent participants (≥ 12 years of age) with sickle cell disease (SCD). Participants will be randomized to receive inclacumab or placebo.
Oakland, California and other locations
Last updated: